Stefan Weidauer

Suggest Changes
Learn More
OBJECTIVE The goal of this study was to investigate the safety and tolerability of the novel endothelin A (ETA) receptor antagonist clazosentan in patients with subarachnoid hemorrhage (SAH) and its(More)